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Summary
 
Bicyclams are a novel class of antiviral compounds that are highly potent and selective inhibi-
tors of the replication of HIV-1 and HIV-2. Surprisingly, however, when the prototype com-
pound AMD3100 was tested against M-tropic virus strains such as BaL, ADA, JR-CSF, and
SF-162 in human peripheral blood mononuclear cells, the compound was completely inactive.
Because of the specific and potent inhibitory effect of AMD3100 on T-tropic viruses, but not
M-tropic viruses, it was verified that AMD3100 interacts with the CXC-chemokine receptor
CXCR4, the main coreceptor used by T-tropic viruses. AMD3100 dose dependently inhibited
the binding of a specific CXCR4 monoclonal antibody to SUP-T1 cells as measured by flow
cytometry. It did not inhibit the binding of the biotinylated CC-chemokine macrophage in-
flammatory protein (MIP) 1
 
a
 
 or MIP-1
 
b
 
, ligands for the chemokine receptor CCR5 (the main
coreceptor for M-tropic viruses). In addition, AMD3100 completely blocked (
 
a
 
) the Ca
 
2
 
1
 
 flux at
100 ng/ml in lymphocytic SUP-T1 and monocytic THP-1 cells, and (
 
b
 
) the chemotactic re-
sponses of THP-1 cells induced by stromal cell–derived factor 1
 
a
 
, the natural ligand for
CXCR4. Finally, AMD3100 had no effect on the Ca
 
2
 
1
 
 flux induced by the CC-chemokines
MIP-1
 
a
 
, regulated on activation normal T cell expressed and secreted (RANTES; also a ligand
for CCR5), or monocyte chemoattractant protein 3 (a ligand for CCR1 and CCR2b), nor was
it able to induce Ca
 
2
 
1
 
 fluxes by itself. The bicyclams are, to our knowledge, the first low mo-
lecular weight anti-HIV agents shown to act as potent and selective CXCR4 antagonists.
 
T
 
he bicyclam derivatives were described several years
ago as potent and selective inhibitors of HIV type 1
and type 2 replication (1, 2). AMD3100, previously called
JM3100 (2) or SID791 (3), exhibits anti-HIV potency at
concentrations of 1–10 ng/ml, with a selectivity index
 
>
 
100,000 (2). Based on time-of-addition experiments, the
compound has been assumed to interact with the HIV fu-
sion-uncoating process, but does not inhibit virus binding
to the CD4 receptor (1, 2). AMD3100 blocks syncytium
formation at a concentration that is 10–100-fold higher
than the concentration required to inhibit virus infection
(1). The 
 
env
 
 glycoprotein (gp)120 has been considered the
major target molecule for this class of compounds because,
for viruses that were made resistant to the bicyclams, a
number of mutations accumulated in the gp120, especially
in the V3-V4 region (3, 4).
Numerous publications over the last year have demon-
strated the importance of chemokine receptors for HIV entry.
Chemokines are chemotactic cytokines, which are classified
as CC or CXC, depending on the positioning of conserved
cysteine residues. Fusin/LESTR, now designated CXC-
chemokine receptor 4 (CXCR4), mediates entry of T-tropic
viruses (5, 6) which can be inhibited by its natural ligand,
the CXC-chemokine stromal cell–derived factor 1
 
a
 
 (SDF-
1
 
a
 
) (7, 8). The CC-chemokine receptor, CCR5, mediates
entry of M-tropic viruses (9–13) and the CC-chemokines
regulated on activation normal T cell expressed and secreted
(RANTES), macrophage inflammatory protein (MIP) 1
 
a
 
and MIP-1
 
b
 
 have been shown to inhibit the replication of
M-tropic viruses (14). Moreover, M-tropic 
 
env
 
 proteins
can interact directly with CCR5 (15, 16).
In previous studies AMD3100 was shown to inhibit the
replication of T-tropic HIV strains or clinical isolates in T cell
lines (such as MT-4, MOLT-4, or CEM cells; references
1–4). While verifying whether AMD3100 was active against
M-tropic viruses in PBMCs, we found that AMD3100
does not inhibit M-tropic viruses such as BaL, ADA, JR-
CSF, and SF-162. Here we show that AMD3100 selec-
tively inhibits the binding of a CXCR4-specific mAb, but
not the binding of biotinylated human MIP-1
 
a
 
 or MIP-
1
 
b
 
. The bicyclam was also found to inhibit the Ca
 
2
 
1
 
 flux
and the chemotactic response induced by SDF-1
 
a
 
 but not
such effects induced by RANTES, MIP-1
 
a
 
, or monocyte
chemoattractant protein 3 (MCP-3).
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Materials and Methods
 
Viruses, Cells, Cell Lines, and Cell Culture.
 
The HIV-1 T-tropic
viruses IIIB strain and RF strain, the HIV-2 T-tropic ROD
strain, and the HIV-1 M-tropic strains BaL, SF-162, ADA, and
JR-FL were all obtained through the Medical Research Council
AIDS reagent project (Herts, UK). The HIV-1 T-tropic molecu-
lar clone NL4-3 was obtained from the National Institute of Al-
lergy and Infectious Disease AIDS reagent program (Bethesda,
MD). The CD4
 
1
 
 lymphocytic SUP-T1 and the CD4
 
1
 
 mono-
cytic THP-1 cell lines were obtained from the American Type
Culture Collection (Rockville, MD). PBMC from healthy do-
nors were isolated by density gradient centrifugation and stimu-
lated with PHA at 1 
 
m
 
g/ml (Sigma Chemical Co., Bornem, Bel-
gium) for 3 d at 37
 
8
 
C. The activated cells (PHA-stimulated blasts)
were washed three times with PBS, and viral infections were
done as described by Cocchi et al. (14). HIV-infected or mock-
infected PHA-stimulated blasts were cultured in the presence of
25 U/ml of IL-2 and varying concentrations of AMD3100, SDF-
1
 
a
 
, and RANTES. Supernatant was collected at days 6 and 10,
and HIV-1 core antigen in the culture supernatant was analyzed
by the p24 ELISA kit from DuPont-Merck Pharmaceutical Co.
(Wilmington, DE) and for HIV-2 detection the INNOTEST
from Innogenetics (Temse, Belgium) was used.
 
Chemokines and mAbs.
 
Recombinant human SDF-1
 
a
 
 was
purchased from PeproTech (London, UK) and human RANTES
and human MIP-1
 
a
 
 were purchased from R & D Systems, Inc.
(Abingdon, UK). MCP-3 was chemically synthesized according
to the published protein sequence (17). The biotinylated human
MIP-1
 
a
 
 and MIP-1
 
b
 
 fluorokine
 
TM
 
 kits were purchased from
R & D Systems Inc. The mAb, termed 12G5, reacts specifically with
the human CXCR4 and was initially provided by Dr. James A.
Hoxie (University of Pennsylvania, Philadelphia, PA) and later
purchased from R & D Systems Inc.
 
Analysis of CXCR4 Expression.
 
SUP-T1 cells were incubated
with AMD3100 or SDF-1
 
a
 
 (at different concentrations) or PBS
for different time periods (1 or 15 min) and at different tempera-
tures (on ice or at room temperature) and the cells were washed
once with PBS. The 12G5 mAb (10 
 
m
 
g/ml) was then added for
30 min at room temperature. The cells were washed twice in
PBS and then incubated with FITC-conjugated goat anti–mouse
Ab (Caltag Labs, San Francisco, CA) for 30 min at room temper-
ature and washed twice in PBS. The binding of the biotinylated
human MIP-1
 
a
 
 was performed according to the protocol of the
manufacturer. Cells were analyzed by a FACScan
 
Ò
 
 flow cytometer.
The percentage of positive cells and the mean fluorescence inten-
sity (MFI) values are indicated in each histogram. The region for
positivity was defined using a control isotype mAb (Becton Dick-
inson, San Jose, CA). The percentage of inhibition of mAb bind-
ing in the presence of different concentrations of chemokine or
compound was calculated using the MFI values, as previously de-
scribed (18).
 
Measurement of Intracellular Calcium Concentrations and Chemotac-
tic Assay.
 
The determination of intracellular calcium concentra-
tions [Ca
 
2
 
1
 
]
 
i
 
 was carried out as previously described (19). In brief,
THP-1 cells or SUP-T1 cells were loaded with Fura-2 (Molecu-
lar Probes, Leiden, The Netherlands). Fura-2 fluorescence was
measured in a luminescence spectrophotometer, fitted with a wa-
ter-thermostatable, stirred four-position cuvette holder (Perkin-
Elmer, Norwalk, CT). Cells were first stimulated with dilution
buffer (control) or AMD3100 or 12G5 mAb at different concen-
trations. As a second stimulus, chemokines were used at an opti-
mal concentration to induce a maximal [Ca
 
2
 
1
 
]
 
i
 
 increase. The sec-
ond stimulus was added 100 s after the first stimulus. The
percentage of inhibition of the [Ca
 
2
 
1
 
]
 
i
 
 increase in response to the
second stimulus was calculated. Chemotaxis of THP-1 cells was
measured in the microchamber assay (5 
 
m
 
m pore membrane) es-
sentially as previously described (17, 20). For inhibition of
chemokine activity by AMD3100, the compound was added to
the cells just before transfer to the upper compartment of the
chemotaxis chamber containing chemokine in the lower com-
partment (20). Chemotactic activities are expressed as indexes 
 
6
 
SEM (17).
 
Results
 
Antiretroviral Activity Profile of AMD3100.
 
AMD3100 was
active in PHA-stimulated blasts against T-tropic virus strains
such as IIIB, RF, and NL4-3, and also against the HIV-2
ROD strain. The 50% inhibitory concentration (IC
 
50
 
) was
between 2 and 7 ng/ml (Table 1). Surprisingly, AMD3100
was completely inactive against four different M-tropic vi-
rus strains (IC
 
50
 
 
 
.
 
25 
 
m
 
g/ml; Table 1). These M-tropic vi-
rus strains mainly use the chemokine receptor CCR5, but
some can also use other chemokine receptors such as
CCR2b and CCR3 (but not CXCR4) to enter the target
cells (9–13). As controls, SDF-1
 
a
 
 and RANTES were in-
cluded and, as can be seen in Table 1, there was no activity
of RANTES (up to 1 
 
m
 
g/ml) against the T-tropic virus
strains, whereas the IC
 
50
 
 of SDF-1
 
a
 
 varied between 20 and
100 ng/ml against the T-tropic virus strains. The opposite
activity profile of these two chemokines was observed with
M-tropic viruses. Here, RANTES had IC
 
50
 
 values be-
tween 4 and 25 ng/ml, whereas SDF-1
 
a
 
 was not active up
to 1 
 
m
 
g/ml. AMD3100 was not active against several sim-
ian immunodeficiency virus (SIV) strains such as MAC,
MND, and AGM in MT-4 or MOLT-4 cells (2), which
use CCR5 rather than CXCR4 as the main coreceptor to
enter human T cells (21).
 
AMD3100 Dose Dependently Inhibits the Binding of a CXCR4-
specific mAb.
 
Because of the specific and potent inhibitory
effect of AMD3100 on T-tropic viruses and not on M-tropic
viruses (or SIV), it was verified that AMD3100 interacts
with CXCR4. The mAb 12G5 reacts specifically with the
human CXCR4 protein and recognizes this receptor on
many T cell lines such as the SUP-T1 cells (22). AMD3100
dose dependently interacted with the CXCR4 receptor, as
shown in Fig. 1. Indeed, AMD3100 at 1 
 
m
 
g/ml completely
inhibited the binding of the mAb 12G5 to CXCR4 on
SUP-T1 cells, as measured by flow cytometry. At 100, 10,
1, and 0.1 ng/ml, AMD3100 still blocked the mAb binding
for 79, 70, 24, and 9% respectively. SDF-1
 
a
 
 competed, as
expected, with the binding of the CXCR4 mAb to its re-
ceptor. SDF-1
 
a
 
 inhibited the binding of the mAb for 83%
at 2 
 
m
 
g/ml and for 54% at 200 ng/ml. Even when washed
away before addition of the mAb, AMD3100 inhibited the
binding of the CXCR4 mAb as efficiently as when the
compound was present during the whole incubation period
with the mAb. Adding AMD3100 only 1 min before the
CXCR4 mAb still blocked the binding of the mAb as effi-
ciently as adding the compound 15 min before the mAb
(data not shown). Irrespective of whether the staining was 
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performed on ice or at room temperature, identical results
were obtained with AMD3100 for inhibition of the bind-
ing of the CXCR4 mAb.
In contrast, even at 25 
 
m
 
g/ml AMD3100 did not inhibit
the binding of biotinylated human MIP-1
 
a
 
 to THP-1
cells, whereas, as control, the anti-human MIP-1
 
a
 
 block-
ing Ab included in the fluorokine
 
TM
 
 kit almost completely
blocked the binding of the biotinylated MIP-1
 
a
 
 (Fig. 2).
Identical results were obtained with the biotinylated hu-
man MIP-1
 
b
 
 fluorokine
 
TM
 
 kit (data not shown).
 
AMD3100 Specifically Blocks SDF-1
 
a
 
–induced Ca
 
2
 
1
 
 Fluxes
and Chemotaxis.
 
We next examined the inhibitory effect
of AMD3100 on the SDF-1
 
a
 
–induced increase in [Ca
 
2
 
1
 
]
 
i
 
(Ca
 
2
 
1
 
 flux). Because the lymphocytic SUP-T1 cells did
not respond in the Ca
 
2
 
1
 
 flux assays to the CC-chemokines
RANTES and MIP-1
 
a
 
, we used the monocytic THP-1 cell
line, which is responsive to these chemokines. This allowed us
to test the chemokine receptor specificity of AMD3100. In
addition, the THP-1 cells were positive for CXCR4 ex-
pression, as measured by flow cytometry with the CXCR4
mAb (data not shown). THP-1 cells also dose dependently
responded in the Ca
 
2
 
1
 
 flux assay to SDF-1
 
a
 
, and half-max-
imal increases in [Ca
 
2
 
1
 
]
 
i
 
 were obtained with 10 ng/ml (data
not shown). As a control for receptor usage, 10 
 
m
 
g/ml of
the CXCR4 mAb was found to completely inhibit the
SDF-1
 
a
 
–induced Ca
 
2
 
1
 
 flux and at 1 
 
m
 
g/ml of the mAb
there was still 36% inhibition (data not shown). AMD3100
at 100 ng/ml completely blocked [Ca
 
2
 
1
 
]
 
i
 
 increases induced
by 30 ng/ml SDF-1
 
a
 
 in both SUP-T1 and THP-1 cells
(Table 2). Lower doses of AMD3100 (10 and 1 ng/ml) still
conferred partial inhibition (35–69%) of Ca
 
2
 
1 increase in-
duced by SDF-1a (Fig. 3; Table 2). In addition, the THP-1
cells responded to RANTES, MIP-1a, and MCP-3, but
no inhibition whatsoever was seen when AMD3100 was
added at 100 ng/ml before addition of the chemokines
(Fig. 4; data not shown). Finally, to confirm the inhibitory
effect of AMD3100 on functional CXCR4 binding and
signaling, chemotaxis assays were performed. Similar to
monocytes (23), THP-1 cells dose dependently responded
to SDF-1a. On THP-1 cells, 100 ng/ml resulted in a half-
maximal chemotactic index (11 6 4; n 5 3). The chemotac-
tic effect of SDF-1a (100 ng/ml) was completely blocked in
the presence of AMD3100 at 10 mg/ml (chemotactic index:
1.3 6 0.6; n 5 3), whereas 1 mg/ml of AMD3100 resulted
in a partial reduction of the chemotactic index (4.3 6 0.7;
n 5 3). AMD3100 alone induced no chemotactic response
on THP-1 cells when tested at a concentration range from
0.01 to 10 mg/ml.
Table 1. The Anti-HIV Activity Profile of AMD3100 Correlated with Coreceptor Use
IC50 (ng/ml)
Strain Coreceptor used ADM3100 SDF-1a RANTES
T-tropic
HIV-1 IIIB CXCR4 2 20 .1,000
HIV-1 RF CXCR4 5 50 .1,000
HIV-1 NL4-3 CXCR4 3 100 .1,000
HIV-2 ROD CXCR4 7 55 .1,000
M-tropic
HIV-1 BaL CCR5 .25,000 .1,000 25
HIV-1 SF-162 CCR5 .25,000 .1,000 5
HIV-1 ADA CCR5 (CCR2b, CCR3) .25,000 .1,000 10
HIV-1 JR-FL CCR5 (CCR2b, CCR3) .25,000 .1,000 4
Effect of AMD3100, SDF-1a, and RANTES on the replication of T-tropic and M-tropic HIV strains in PHA-stimulated blasts. Virus yield was
monitored in the cell-free supernatant 6–10 d after infection by viral Ag ELISA. Results represent mean values for three separate experiments from
three different PBMC donors.
Figure 1. Inhibition of the binding of the anti-CXCR4 mAb to SUP-
T1 cells in the presence of AMD3100 at 1 mg/ml (C) and SDF-1a (2 mg/
ml; D). In A an isotype control mAb and in B the specific anti-CXCR4
mAb were used. The percentage of positive cells and the MFI values are
indicated in each histogram.1386 Potent Inhibition of HIV Infectivity by a Specific CXCR4 Antagonist
Discussion
CXCR4 is the coreceptor that promotes entry of T-tropic
HIV strains (7, 8), whereas CCR5 allows entry of M-tropic
HIV strains (9–13). SDF-1a, the natural ligand for CXCR4,
has been shown to inhibit T-tropic viruses and primary
HIV isolates through CXCR4 blockage (6, 7). AMD3100
is a bicyclam active against a broad range of T-tropic HIV-1
and HIV-2 strains (IC50: 1–10 ng/ml), but not against
M-tropic HIV-1 strains (Table 1) such as BaL, ADA, SF-162,
and JR-FL (IC50 .25 mg/ml). AMD3100 is able to inhibit
the replication of HIV-2 strains such as ROD, but these virus
strains also use CXCR4 to enter the cells (24). In addition,
AMD3100 is not active against several SIV strains (2), and
recently it was demonstrated that not only the M-tropic SIV
strains but also the T-tropic SIV strains use CCR5, and not
CXCR4, as the main coreceptor to enter human T cells (21).
The specific antiviral activity profile of AMD3100 sug-
gests that it might directly interact with the CXCR4 re-
ceptor. This study brings evidence to support this hypothe-
sis, at both the level of binding and of signaling. AMD3100
not only inhibits the binding of CXCR4 mAb to its recep-
tor (Fig. 1), it also inhibits the intracellular SDF-1a signal-
ing in a dose-dependent fashion (Table 2). The CXCR4
mAb, 12G5, is reported to inhibit HIV-1 and HIV-2 infec-
tion at 1–20 mg/ml, although the ability of this mAb to
block infection of T-tropic isolates of HIV-1 is highly de-
pendent on the viral isolate and the target cell; occasionally,
it is even inactive against T-tropic viruses (23). Very potent
and far less variable antiviral activity is seen with AMD3100
(IC50: 1–10 ng/ml, 50% cytotoxic concentration [CC50]
.100  mg/ml; reference 2), indicating a very strong interac-
tion of AMD3100 with the CXCR4 receptor.
Although the interaction of the bicyclams with CXCR4
has been unequivocally demonstrated in this study, inter-
ference either with other (still unknown) CXCR4-like or
other chemokine receptors used by SDF-1a cannot be ex-
cluded at this moment. At present there is no evidence that
the CXCR4 mAb and SDF-1a can recognize receptors
other than CXCR4. AMD3100 does not appear to inter-
fere with CCR5 as there is no inhibitory effect of AMD3100
on the replication of SIV and M-tropic HIV-1 strains in
PBMC. Moreover, AMD3100 does not inhibit the binding
of either of the biotinylated CC-chemokines, MIP-1a
(Fig. 2) and MIP-1b, nor does it block the Ca21 flux in-
duced by RANTES (Fig. 4) or MIP-1a, although it mark-
edly inhibited the Ca21 flux induced by SDF-1a (Fig. 3).
The bicyclam also did not inhibit the Ca21 flux induced by
Figure 2. Lack of inhibition of the binding of biotinylated MIP-1a to
THP-1 cells in the presence of AMD3100 (25 mg/ml; C). In A only the
avidin-FITC was added, in B the biotinylated MIP-1a and avidin-FITC
were added, in C AMD 3100 (25 mg/ml) was added, and in D the block-
ing Ab was added. The percentage of positive cells and MFI values are in-
dicated in each histogram.
 
Table 2. Inhibition of SDF-1a–induced Ca21 Flux by AMD3100 in SUP-T1 and THP-1 Cells
Stimulus SUP-T1 cells [Ca21]i increase THP-1 cells [Ca21]i increase 
AMD3100
(first)
SDF-1a
(second) exp. 1 exp. 2 exp. 3
mean percentage
of inhibition exp. 1 exp. 2 exp. 3
mean percentage
of inhibition
ng/ml ng/ml nM % nM %
100 0 0 0 0 0 0 0
100 30 ,10* ,10 ,10 >90 ,8 ,8 ,8 .90
10 30 83 33 49 45 31 37 ND 69
13 0 N D 3 9 7 8 3 5 N D 5 6 N D 5 9
0.1 30 ND ND 90 ,10 ND ND ND
0 30 110 89 91 0 87 136 65 0
*Results of individual Ca21 flux assays are given.
Figure 3. Inhibition of SDF-
1a–induced Ca21 fluxes in
SUPT-1 cells by AMD3100 pre-
treatment (first stimulus; 1st) at
100 ng/ml and 10 ng/ml. SDF-
1a was given as second stimulus
(2nd) at 30 ng/ml.1387 Schols et al. Brief Definitive Report
MCP-3, a natural ligand for CCR1 and CCR2b (25). By
itself AMD3100 did not induce [Ca21]i increases even at a
concentration of 100 mg/ml (data not shown). The IC50 of
AMD3100 required to inhibit binding of the CXCR4
mAb and to desensitize the SDF-1a–induced Ca21 flux is
between 1 and 10 ng/ml. This dose nicely correlates with
the IC50 of the compound for the replication of T-tropic
viruses in T cell lines and PBMCs, whereas a relatively
higher concentration (10 mg/ml) was necessary to com-
pletely block SDF-1a–induced chemotaxis. This illustrates
that AMD3100 can funtion as a potent antiviral compound
in vitro (1, 2) and in vivo (100 ng/ml in plasma of SCID-
hu mice is sufficient to reduce the viral load significantly;
reference 26), rather than acting as an antagonist of leuko-
cyte chemoattraction.
Some individuals who were repeatedly exposed to HIV
infection and remained uninfected were found to be ho-
mozygous for a 32-bp deletion in the CCR5 (27–29). Per-
haps mutations in CXCR4 and other coreceptors may also
be identified in individuals who are less susceptible to HIV
infection and/or in individuals who have been infected but
do not proceed to AIDS, the so-called long-term nonpro-
gressors (30), who have a predominance of M-tropic vi-
ruses. CCR5-binding viruses are important during early
stages of infection, whereas the CXCR4-binding viruses
emerge later in the progression to AIDS (31). AMD3100,
because of its strong interaction with CXCR4, may be-
come an important antiviral drug in vivo, because of its po-
tential to block infection with T-tropic viruses, which in
most cases precedes the decline in CD41 T cells and the
development of AIDS.
Recently, derivatives of the CC-chemokine RANTES
have been described as CCR5 antagonists with activity
against M-tropic HIV-1 strains (32, 33). However, the bi-
cyclams are the first low molecular weight chemicals among
the anti-HIV agents described as CXCR4 antagonists.
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Figure 4. AMD3100 fails to
inhibit Ca21 fluxes induced by
RANTES in THP-1 cells. Buffer
was added in A and AMD3100
at 100 ng/ml in B as first stimu-
lus (1st), then RANTES was
added at 100 ng/ml as second
stimulus (2nd).
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